The 5 most frequently asked questions about factor Xa inhibitors
Direct oral anticoagulants (DOACs) are commonly used oral factor Xa inhibitors in recent
years. However, in some special clinical situations, the appropriate use of these …
years. However, in some special clinical situations, the appropriate use of these …
Comparison of Direct Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Obese or Overweight Patients: A Retrospective …
JC Cook, TE Wiczer, AT Gerlach… - Journal of …, 2021 - search.ebscohost.com
BACKGROUND: Direct-acting oral anticoagulants (DOACs) represent an alternative to
vitamin K antagonists in the treatment of venous thromboembolism (VTE); however …
vitamin K antagonists in the treatment of venous thromboembolism (VTE); however …
Venous thromboembolism prevention through the use of novel Factor Xa inhibitors
A Al-Hillan, RS Bajwa, A Cheema, A Ezeume… - Postgraduate …, 2019 - Taylor & Francis
The risk of a venous thromboembolic event is not limited to the pre-hospital, hospital, or
immediate post-hospital period. Because of challenges with data collection, the risk of …
immediate post-hospital period. Because of challenges with data collection, the risk of …
Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database
Y Qian, X Zhao, D Liu, J Liu, Z Yue… - Expert Opinion on Drug …, 2024 - Taylor & Francis
ABSTRACT Objectives Direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban,
commonly used direct oral anticoagulant (DOAC), are widely used to prevent and treat …
commonly used direct oral anticoagulant (DOAC), are widely used to prevent and treat …
Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations
N van Es, HR Büller - Hematology 2014, the American Society …, 2015 - ashpublications.org
The major practical advantage of the direct oral anticoagulants (DOACs), comprising the
thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban, edoxaban, and …
thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban, edoxaban, and …
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism
BI Eriksson, DJ Quinlan… - Annual review of …, 2011 - annualreviews.org
The last decade has seen the evaluation of several new oral anticoagulants that directly
target thrombin or activated factor X (FXa). All demonstrate a rapid onset of action, a low …
target thrombin or activated factor X (FXa). All demonstrate a rapid onset of action, a low …
Direct Oral Anticoagulants
NS Evans - Anticoagulation Therapy, 2018 - Springer
Four direct oral anticoagulants (DOACs)—dabigatran, a direct thrombin inhibitor, and the
direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban—have been approved for …
direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban—have been approved for …
Up and down in gastrointestinal cancer and bleeding with direct oral anticoagulants
AJM Martín, JS Alsar, LO Morán - European Journal of Internal …, 2024 - ejinme.com
Although direct oral anticoagulants (DOACs) have been established as an effective option
for cancer-associated thrombosis (CAT), there are still concerns about their safety in patients …
for cancer-associated thrombosis (CAT), there are still concerns about their safety in patients …
[引用][C] Use of anti-factor Xa levels in cancer patients taking direct oral anticoagulants
Z Sayar, A Weatherill, C Gates… - Thrombosis …, 2021 - thrombosisresearch.com
Use of direct oral anticoagulants (DOACs), particularly the direct factor Xa inhibitors,
rivaroxaban and apixaban, as prophylaxis for venous thromboembolism (VTE)[1, 2] and/or …
rivaroxaban and apixaban, as prophylaxis for venous thromboembolism (VTE)[1, 2] and/or …
[HTML][HTML] Exploring indications for the use of direct oral anticoagulants and the associated risks of major bleeding
TJ Milling Jr, JA Frontera - The American journal of managed care, 2017 - ncbi.nlm.nih.gov
Thrombosis is a leading cause of morbidity and mortality in the United States. Arterial and
venous thromboses are implicated in the pathogenesis of major disorders, including …
venous thromboses are implicated in the pathogenesis of major disorders, including …